+++ Einfach investieren ? mit Kapitalschutz oder Teilschutz ? raiffeisenzertifikate.at ? jetzt in Zeichnung +++ -W-
29.07.2021 23:13:00

BD to Present at UBS Genomics 2.0 and MedTech Innovations Summit

FRANKLIN LAKES, N.J., July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that management will be presenting at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021, at 4:00 p.m. Pacific Time (PT)/7:00 p.m. Eastern Time (ET).

The webcast can be accessed through BD's investor relations website at www.bd.com/investors and will be available for replay for a minimum of seven days after the conference. Any related materials will be posted on the BD investor relations website no later than 7:00 a.m. ET on Wednesday August 11, 2021.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:




Media                                                  

Investors

Troy Kirkpatrick                                       

Kristen M. Stewart, CFA

VP, Public Relations                               

SVP, Strategy & Investor Relations

858.617.2361                                            

201.847.5378        

troy.kirkpatrick@bd.com                          

kristen.stewart@bd.com  

 

 

Cision View original content:https://www.prnewswire.com/news-releases/bd-to-present-at-ubs-genomics-2-0-and-medtech-innovations-summit-301344768.html

SOURCE BD (Becton, Dickinson and Company)

Analysen zu Becton, Dickinson & Co. (BD)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Becton, Dickinson & Co. (BD) 214,70 0,05% Becton, Dickinson & Co. (BD)